Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

May 17, 2024

Sol-Gel, Beimei sign deal for TWYNEO commercialisation

Sol-Gel Technologies has entered into an asset purchase agreement with Shenzhen Beimei Pharmaceutical, granting the latter exclusive rights to commercialise Sol-Gel’s dermatology product TWYNEO in mainland China, Taiwan, Hong Kong, Macau, and Israel.  

Sol-Gel, Beimei sign deal for TWYNEO commercialisation